Very legit question, one we all want to know. What I do know definitely, was this latest raise brought in the cash needed to “qualify” for an uplist. Without that raise, the ability to uplist did not exist currently. I don’t know specific financials for that, nor do I know if we don’t uplist within 3-4 months, if our cash on hand then dwindles to a level that does not qualify for uplist. And then would we have to raise more capital again? What I do know, definitely, is that David and co want to uplist ASAP. But we cannot do it here at .20, with zero momentum.
Therefore, again I know these road shows and the 5/10 demonstration of SPORT at Columbia are being done to further create awareness and interest in Titan, both retail (to a smaller extent) and institutional (support once we uplist as US and European funds don’t want to touch an OTC company).
David has done this before and I believe has a plan for how he is going to accomplish it with Titan. Have to get catalysts first, momentum, etc then uplist, then support and further catalysts. Design freeze and FDA submission are the two largest, does he have more in the tank before then? I think so. COB replacement, other directors, further updates on development, more patents / increased IP portfolio, surgeon feedback - perhaps new surgeries capable to perform, release of partners, non-dilutive financing such as exclusive distribution rights, etc. Perhaps others can add to this exciting list.
I just rack my brain, along with many other investor friends / family, of which many have medical backgrounds, and try to figure out why we are here at these depressed pps levels and how this does not work out BIG in the end. Especially for this who have a cost basis between .20-.60 USD....
That above was done quickly, so happy to re-evaluate / update once you reply.
News 
Market Data 
Discover 
